Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticles

The application of nanotechnology to drug delivery systems for cancer therapy has progressively received great attention. The most heavily investigated approach is the development of nanoparticles (NPs) utilizing biodegradable and biocompatible polymers such as poly (lactic-co-glycolic acid) (PLGA)....

Full description

Bibliographic Details
Main Authors: Heba S. Elsewedy, Bandar E. Al Dhubiab, Mahmoud A. Mahdy, Hanan M. Elnahas
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Drug Delivery
Subjects:
peg
Online Access:http://dx.doi.org/10.1080/10717544.2020.1797237
id doaj-474e63766d424194a36638703d0b51e2
record_format Article
spelling doaj-474e63766d424194a36638703d0b51e22021-07-06T11:30:11ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642020-01-012711134114610.1080/10717544.2020.17972371797237Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticlesHeba S. Elsewedy0Bandar E. Al Dhubiab1Mahmoud A. Mahdy2Hanan M. Elnahas3Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig UniversityDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal UniversityDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig UniversityDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig UniversityThe application of nanotechnology to drug delivery systems for cancer therapy has progressively received great attention. The most heavily investigated approach is the development of nanoparticles (NPs) utilizing biodegradable and biocompatible polymers such as poly (lactic-co-glycolic acid) (PLGA). These NPs could be further improved by surface modification utilizing a hydrophilic biodegradable polymer such as polyethylene glycol (PEG) to achieve passive targeting. Modified NPs can deliver drugs such as brucine (BRU), which has shown its potential in cancer therapy. The objective of the current investigation was to develop and evaluate the passive targeting of long-circulating PLGA NPs loaded with BRU. NPs were characterized in terms of drug-excipient compatibility studies, including FTIR and DSC; physicochemical evaluations including particle size, zeta potential, morphological evaluation, entrapment efficiency and percentage yield; total serum protein adsorbed onto NP surfaces; and in vitro release of the loaded drug. Factorial design was employed to attain optimal PLGA-loaded NPs. Finally, the in vivo anti-tumor activity of BRU-loaded PLGA NPs was evaluated in tumor-bearing mice. The NPs obtained had smooth surfaces with particle sizes ranged from 94 ± 3.05 to 253 ± 8.7 nm with slightly positive surface charge ranged from 1.09 ± 0.15 to 3.71 ± 0.44 mV. Entrapment of BRU ranged between 37.5 ± 1.8% and 77 ± 1.3% with yields not less than 70.8%. Total protein adsorbed was less than 25.5 µg total protein/1 mg NP. In vitro drug release was less than 99.1% at 168 h. Finally, significant reductions in tumor growth rate and mortality rate were observed for PEG PLGA NP formulations compared to both BRU solution and naked NPs.http://dx.doi.org/10.1080/10717544.2020.1797237nanoparticleoptimizationplgapegbrucine
collection DOAJ
language English
format Article
sources DOAJ
author Heba S. Elsewedy
Bandar E. Al Dhubiab
Mahmoud A. Mahdy
Hanan M. Elnahas
spellingShingle Heba S. Elsewedy
Bandar E. Al Dhubiab
Mahmoud A. Mahdy
Hanan M. Elnahas
Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticles
Drug Delivery
nanoparticle
optimization
plga
peg
brucine
author_facet Heba S. Elsewedy
Bandar E. Al Dhubiab
Mahmoud A. Mahdy
Hanan M. Elnahas
author_sort Heba S. Elsewedy
title Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticles
title_short Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticles
title_full Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticles
title_fullStr Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticles
title_full_unstemmed Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticles
title_sort development, optimization, and evaluation of pegylated brucine-loaded plga nanoparticles
publisher Taylor & Francis Group
series Drug Delivery
issn 1071-7544
1521-0464
publishDate 2020-01-01
description The application of nanotechnology to drug delivery systems for cancer therapy has progressively received great attention. The most heavily investigated approach is the development of nanoparticles (NPs) utilizing biodegradable and biocompatible polymers such as poly (lactic-co-glycolic acid) (PLGA). These NPs could be further improved by surface modification utilizing a hydrophilic biodegradable polymer such as polyethylene glycol (PEG) to achieve passive targeting. Modified NPs can deliver drugs such as brucine (BRU), which has shown its potential in cancer therapy. The objective of the current investigation was to develop and evaluate the passive targeting of long-circulating PLGA NPs loaded with BRU. NPs were characterized in terms of drug-excipient compatibility studies, including FTIR and DSC; physicochemical evaluations including particle size, zeta potential, morphological evaluation, entrapment efficiency and percentage yield; total serum protein adsorbed onto NP surfaces; and in vitro release of the loaded drug. Factorial design was employed to attain optimal PLGA-loaded NPs. Finally, the in vivo anti-tumor activity of BRU-loaded PLGA NPs was evaluated in tumor-bearing mice. The NPs obtained had smooth surfaces with particle sizes ranged from 94 ± 3.05 to 253 ± 8.7 nm with slightly positive surface charge ranged from 1.09 ± 0.15 to 3.71 ± 0.44 mV. Entrapment of BRU ranged between 37.5 ± 1.8% and 77 ± 1.3% with yields not less than 70.8%. Total protein adsorbed was less than 25.5 µg total protein/1 mg NP. In vitro drug release was less than 99.1% at 168 h. Finally, significant reductions in tumor growth rate and mortality rate were observed for PEG PLGA NP formulations compared to both BRU solution and naked NPs.
topic nanoparticle
optimization
plga
peg
brucine
url http://dx.doi.org/10.1080/10717544.2020.1797237
work_keys_str_mv AT hebaselsewedy developmentoptimizationandevaluationofpegylatedbrucineloadedplgananoparticles
AT bandarealdhubiab developmentoptimizationandevaluationofpegylatedbrucineloadedplgananoparticles
AT mahmoudamahdy developmentoptimizationandevaluationofpegylatedbrucineloadedplgananoparticles
AT hananmelnahas developmentoptimizationandevaluationofpegylatedbrucineloadedplgananoparticles
_version_ 1721317633495662592